Formulation factors affecting the isomerization rate of betamethasone-17-valerate in a developmental hydrophilic cream – a HPLC and microscopy based stability study by Byrne, Jonathan et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=iphd20
Pharmaceutical Development and Technology
ISSN: 1083-7450 (Print) 1097-9867 (Online) Journal homepage: https://www.tandfonline.com/loi/iphd20
Formulation factors affecting the isomerization
rate of betamethasone-17-valerate in a
developmental hydrophilic cream – a HPLC and
microscopy based stability study
Jonathan Byrne, Anke Wyraz, Trinidad Velasco-Torrijos & Robert Reinhardt
To cite this article: Jonathan Byrne, Anke Wyraz, Trinidad Velasco-Torrijos & Robert Reinhardt
(2017) Formulation factors affecting the isomerization rate of betamethasone-17-valerate in a
developmental hydrophilic cream – a HPLC and microscopy based stability study, Pharmaceutical
Development and Technology, 22:4, 537-544, DOI: 10.3109/10837450.2016.1143003
To link to this article:  https://doi.org/10.3109/10837450.2016.1143003
Published online: 19 Feb 2016.
Submit your article to this journal 
Article views: 114
View Crossmark data
Citing articles: 2 View citing articles 
ISSN: 1083-7450 (print), 1097-9867 (electronic)
Pharm Dev Technol, 2017; 22(4): 537–544
! 2016 Informa UK Limited, trading as Taylor & Francis Group. DOI: 10.3109/10837450.2016.1143003
RESEARCH ARTICLE
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Abstract
The formulation of betamethasone-17-valerate (BV) into topical medicines presents a significant
challenge for the formulation chemist. The substance is susceptible to acid and base catalyzed
isomerization in aqueous environments, which results in valerate transesterification from
carbon 17 to carbon 21 of the steroid ring system. This acyl migration process is of significant
clinical importance since the 21-valerate ester possesses only a fraction of the potency of the
17-valerate parent compound. Isomerization of BV should therefore be reduced to a minimum
through design of a suitable drug vehicle. In this study, the effect of varying the concentration
of several excipient components on the isomerization rate of betamethasone valerate in a
model hydrophilic cream has been investigated. These excipients include the emulsifier
macrogolstearylether-20/21, the co-emulsifier cetylstearyl alcohol and the thickening agent
hydroxyl propyl methylcellulose. Additionally, the influence of pH, the presence of the
antioxidant, alpha-tocopherol, as well as the chelating agent, disodium edetate, on the stability
of the formulation have been investigated. Trial drug product formulations, which were
designed to investigate the influence of the above-mentioned components/parameters were
manufactured and their stability was tested according to current ICH Guidelines. The content,
purity and crystalline structure of the active substance in these formulations was analyzed by a
combination of HPLC and microscopy techniques. The study demonstrates that the rate of
isomerization of betamethasone valerate depends significantly on the concentration of
emulsifier used in the cream formulation. At higher concentrations of emulsifier the
isomerization proceeds rapidly with significant degradation over a period of weeks, whereas
at lower concentrations significant degradation may not be observed, even after several years’
storage. The influence of the emulsifier has been shown to be independent of the pH value of
the aqueous phase of the cream. These findings have not been reported in previous literature
reports on this topic, which have tended to focus on the influence of pH. The results are likely
to be of interest to pharmaceutical chemists working on the formulation of glucocorticoids as
well as to local- and hospital pharmacists who carry out the practice of dilution of proprietary
corticoid preparations, where the choice of diluent is likely to be critical for ensuring the
stability of the diluted product.
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Introduction
Betamethasone is a potent, synthetic corticosteroid with anti-
inflammatory properties, which is employed in the treatment of
inflammatory skin disorders such as eczema and psoriasis. Since
only 12–14% of the administered dose of betamethasone is
absorbed when applied topically1, it must be administered in the
form of one of its esters, such as betamethasone-17-valerate (BV)
or betamethasone-17,21-dipropionate. The esterified forms gen-
erally have increased lipophilic nature allowing for better
penetration of the drug molecule across the lipid membranes of
the skin2,3, thus enhancing the local bioavailability of the
substance. BV is one of the more potent and commonly used
esters of betamethasone and is available in several marketed
products for topical use, such as Betnovate Cream (Glaxo,
Brentford, UK) for monotherapy or together with fusidic acid in
Fusibet Cream (Leo Laboratories, Ballerup, Denmark) for
combinational therapy of inflammatory skin-conditions with
secondary infections.
The formulation of BV into a suitably stable vehicle is not
without problems. The substance is susceptible to an acid and
base catalyzed isomerization in aqueous and semi-solid formula-
tions resulting in an acyl group migration from position C17 to the
more stable C21 position of the steroid ring system4 (Figure 1).
This isomerization process is of significant clinical relevance
since betamethasone-21-valerate demonstrates only &1/15th of
the potency of its 17-valerate counterpart5. In a highly regulated
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environment, such as the pharmaceutical industry, the stability of
pharmaceutical preparations is ensured through extensive analyt-
ical testing. The data generated through this rigorous testing is
used as a basis for justifying the shelf-life of a pharmaceutical
product. In contrast, in a clinical setting, such as in a hospital
pharmacy, physicians often like to prescribe dilutions of topical
corticosteroids, e.g. 1:4 or 1:10 dilutions are typically performed
with available diluents. The purpose of diluting corticosteroid
preparations is usually to reduce the side-effects associated with
their use, such as skin atrophy and pigmentation loss6. The practice
of dilution of marketed corticosteroids appears in principle to be
justified, since numerous studies have shown that the relationship
between concentration and activity of topically applied gluco-
corticoids is not linear6,7, with much weaker dilutions often
demonstrating similar activity to the undiluted product in vaso-
constriction assays8–11. However, since in many cases the diluted
product is not analyzed and little is known regarding its stability,
there may be potential issues regarding safety and efficacy of the
active substances in such dilutions.
Previously published studies on this topic have demonstrated
that the dilution of semi-solid formulations containing BV can
affect the stability of the drug substance. It has been shown that the
choice of diluent plays a crucial role with regard to the
isomerization process. For example, 1:4 dilutions of Betnovate
in Unguentum Merck and white soft paraffin were stable over 12
months10,11, whereas dilutions in Emulsifying Ointment showed
50% degradation within 4.2 h12. Many of the published studies
offered little explanation as to why the diluent was influencing the
isomerization rate. In most cases, the increased rate of isomeriza-
tion was attributed to an increased pH of the diluted preparation,
without consideration of other factors. Boonsaner et al.8 studied the
stability of BV in Beeler’s Basis and Cold Cream. They came to
the conclusion that the degradation rate cannot be solely dependent
on the pH alone and that other unknown factors must be involved. It
was shown that preparations with similar pH values can show very
different stabilities but no evidence was provided as to what these
unknown factors may have been.
In this study, it has been demonstrated that the concentration of
the primary emulsifier in a hydrophilic cream formulation plays a
crucial role with regard to the isomerization rate of BV. The
influence of the concentration of the emulsifiers macrogolstear-
ylether-20/21 (S-20/S-21) as well as the co-emulsifier cetylstearyl
alcohol (CSO) and thickening agent hydroxyl propyl methylcel-
lulose (HPMC) on the isomerization rate in experimental cream
formulations has been investigated. Additionally, the influence of
pH, the presence of the antioxidant, alpha-tocopherol, as well as
the chelating agent, disodium edetate, on the stability of the
formulation have been investigated. The aim of these studies was
to develop a stable pharmaceutical vehicle for the effective
delivery of betamethasone valerate and fusidic acid.
The content, purity and crystalline structure of the drug
substance in each of the formulations has been analyzed by a
combination of HPLC and microscopic techniques. The HPLC
analysis was performed using two novel procedures, which were
specifically developed for this task13,14. This study is the first to
demonstrate that the concentration of emulsifier in the finished
product is of critical importance with regard to the isomerization
of BV and thus its stability in semi-solid formulations.
Materials and methods
Reagents
Gradient grade methanol and acetonitrile were purchased from
VWR International GmbH (Darmstadt, Germany). Purified water
was obtained from the in-house purification system at Mibe
GmbH Arzneimittel (Brehna, Germany). Phosphoric acid (85%
m/m, analysis grade, d¼ 1.71 g/ml) was purchased from Merck
(Darmstadt, Germany). All cream samples were provided by Mibe
GmbH Arzneimittel.
A description of the function and quality of the APIs and
excipients used in the manufacture of the cream is described in
the table.
Ingredient Function Quality
Fusidic acid hemihydrate drug substance Ph. Eur.
Betamethasone-17-valerate drug substance Ph. Eur.
Macrogol stearyl ether 20 emulsifier In-house
specification
Cetylstearylalcohol co-emulsifier Ph. Eur.
Paraffin, liquid ingredient of the oil phase Ph. Eur.
Paraffin, white soft ingredient of the oil phase Ph. Eur.
Hypromellose thickener Ph. Eur.
Citric acidmonohydrate pH modifying agent Ph. Eur.
Methyl parahydroxybenzoate preservative Ph. Eur.
(continued )
Figure 1. Schematic of isomerization followed by hydrolysis of BV.
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Instrumentation
HPLC experiments were performed with Shimadzu Prominence
HPLC Systems (Shimadzu, Tokyo, Japan). The systems were
equipped with a binary pump (LC-20AD), a temperature-
controlled auto-sampler (SIL-20ACHT), a temperature-controlled
column compartment (CTO-20AC) as well as an on-line degasser
(DGU-20A5). A (SPD-M20A) DAD detector was employed. The
software packages used were SHIMADZU LCsolution version
1.24 SP1 and SHIMADZU Class-VP version 6.14 SP2A. Stability
studies were performed in Binder KBF 720 stability chambers
(Binder Inc., Tuttlingen, Germany). Microscopy experiments
were performed with a Nikon Eclipse LV100 polarizing micro-
scope (Nikon, Tokyo, Japan) equipped with diascopic and
episcopic illuminators (LV-UEPI2), a polarizer, a CFIUW 10
binocular, CFI LU Plan Fluor Epi P 5, 10, 20, 40 and
100 objectives and a DS-Fi2 camera unit. Analysis of the
micrographs was performed using NIS-Elements AR software
version v.4.2. The HPLC conditions and sample preparation
procedure are described in the literature13,14.
Experimental procedures
Solubility in paraffin
BV (60.0 mg) was weighed into a 50-ml centrifuge tube and 15 ml
of liquid paraffin was added. The resulting suspension was shaken
in a water-bath at 65 C for 4 h.
Solubility in aqueous solutions of emulsifier
Ten milligrams of BV was weighed into a 50-ml centrifuge tube
and mixed with 25 ml of aqueous solutions of S-21 of varying
concentration over the range 0.0–1.0% of the emulsifier. The
mixtures were shaken for 4 h in a water-bath at 65 C and allowed
to cool to room temperature. The pH of each mixture was
recorded and the mixtures were filtered through a 0.45-mm
regenerated cellulose syringe filter into a vial before HPLC
analysis.
Preparation of cream samples
Cream formulations were manufactured in several steps. In the
first step, macrogolstearylether-20/21 (S-20/S-21), CSO, liquid
paraffin and white soft paraffin were melted by heating in a
suitable vessel under stirring. Next, the aqueous phase was
prepared by dissolving the required quantities of the preservative
compounds potassium sorbate as well as methyl- and propyl
paraben in purified water. Both the aqueous and oil phases were
mixed and homogenized by stirring under heating for an
appropriate length of time forming a cream base. A gel phase
was then prepared by dissolving the required quantities of citric
acid monohydrate and HPMC in purified water by stirring at
elevated temperature. The gel phase was added to the cream base
and the homogenization procedure was repeated. Finally, an
active substance suspension was prepared by suspending the API
in liquid paraffin. This suspension was then homogenized and
added to the cream at elevated temperature. The cream was
allowed to cool before being homogenized for a final time.
Results
Initial trial batches
Initially, a number of trial formulations were prepared with
varying quantities of selected excipients. The proportions of S-20,
CSO and hydroxylpropyl methylcellulose (HPMC) contained in
these formulations are provided in Table 1. For the purposes of
this study, the batches have been labeled as variants A, B, C and
D. Variant A also contained 0.1% of the antioxidant alpha-
tocopherol, which was added to investigate if oxidative processes
were likely to affect the stability of the drug substance. The
quantities of all other ingredients of the cream as well as the
manufacturing procedure and equipment were similar for all
batches. In each case, the pH was adjusted to 5.0 ± 0.2 and the
active pharmaceutical ingredient was present in suspended form
in the cream matrix.
The stability of each of the trial batches was determined after
storage for 1 month under real-time (25 C/60% RH) and
accelerated (40 C/75% RH) conditions (see Figure 2 for a
representative example chromatogram). The results indicated that
variant D was markedly more stable than any of the other variants
with regard to the isomerization rate (Figure 3a). Variants A, B
and C contained approximately 3–4% of the isomerization product
betamethasone-21-valerate after storage for 1 month at 25 C/60%
RH. This level of degradation was considered unacceptable since
this quantity of impurity would normally be expected to be
present after 24–36 months storage in a comparable pharmaceut-
ical product. Furthermore, current guidelines15,16 require that the
content of the drug substance should lie between 95% and 105%
or, if justified, between 90% and 105% of the label claim
throughout the shelf-life of the product. The above results
indicated that the API would have been completely degraded
after 36 months, if the isomerization had continued at a
linear rate.
The data also seemed to indicate that reducing the quantity of
HPMC from 1.00% to 0.50% may slow the rate of isomerization,
whereas, in contrast, increasing the quantity of HPMC from
1.00% to 2.00% did not affect the stability of BV. Decreasing the
quantity of S-20 to 3.65% in combination with an increase of CSO
to 6.35% may also influence the rate of isomerization. As evident
by a comparison of the data from variants A and B, the addition of
0.1% alpha-tocopherol to the formulation has no effect on the rate
of isomerization. It was therefore concluded that oxidative
Ingredient Function Quality
Propylparahydroxybenzoate preservative Ph. Eur.
Potassium sorbate preservative Ph. Eur.
Water, purified solvent Ph. Eur.
Table 1. The percentages of S-20, CSO and HPMC in the first trial variants A, B, C and D.
Variant A Variant B Variant C Variant D
Article Description Proportion in mass % Proportion in mass % Proportion in mass % Proportion in mass %
1 Macrogolstearylether-20 (S-20) 5.00 5.00 5.00 3.65
2 Cetylstearyl alcohol (CSO) 5.00 5.00 5.00 6.35
3 Hypromellose (HPMC) 1.00 1.00 2.00 0.50
4 a-Tocopherol 0.1% – – –
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degradation processes are unlikely to play a role in the observed
degradation of BV in the investigated hydrophilic formulation.
Optimization – round I
Despite the observed trend, the stability of the first trial batches
proved to be unacceptable and it was therefore necessary to
optimize the formulation. The compositions of the optimized trial
formulations are provided in Table 2. These formulations were
subjected to stability studies in a similar fashion to the initial
batches and tested by HPLC. The 5 months real time data
presented in Figure 3(b) demonstrate that increasing the content
of HPMC from 0.50% to 1.00% accelerates the rate of
isomerization. In contrast, a reduction of the quantity of
Steareth-20 from 5.00% (variant B) to 2.14% (variant E) coupled
with an increase of the quantity of CSO from 5.00% (variant B) to
7.86% (variant E) appeared to slow the rate of isomerization.
Replacing S-20 with macrogolstearylether-21 (S-21) may slow the
rate of isomerization, whereas suspending the API in the aqueous
phase of the cream, as opposed to the oil phase, does not stabilize
the formulation.
HPMC is present in the formulation as a thickening agent,
which should not affect the stability of BV. However, according to
the Technical Handbook for METHOCEL Cellulose Ethers from
Figure 3. (a) Initial trial batches – content of betamethasone-21-valerate after storage for 1 month at 25 C/60% RH. (b) Optimized formulations –
content of betamethasone-21-valerate after storage for 5 months at 25 C/60% RH. (c) Influence of pH on the isomerization rate of BV in aqueous
solution within the pH range 1.2–8.2 after 48 h. (d) Influence of the concentration of steareth-21 on the solubility of BV in an aqueous medium.
Figure 2. Example chromatogram from
the purity test of a degraded cream sample
analyzed after stressing under the conditions
of 40 C/75% RH at pH 7 for 2 months. The
sample demonstrated significant degradation.
HPLC conditions as provided in Table 1.
Peak 3 was not present in this particular
sample. 1, Betamethasone; 2, 24,25-dihydro-
24,25-dihydroxyfusidic acid; 3, 24,25-dihy-
dro-24,25-dihydroxyfusidic acid-21,25-lac-
tone; 4, betamethasone-17-valerate; 5, (24R)-
24,25-dihydro-24,25-dihydroxyfusidic acid
21,24-lactone; 6, 26-hydroxyfusidic acid; 7,
(24S)-24,25-dihydro-24,25-dihydroxyfusidic
acid 21,24-lactone; 8, Betamethasone-21-
valerate; 9, 26-oxofusidic acid; 10, 3-dide-
hydrofusidic acid; 11, 11-didehydrofusidic
acid; 12, 16-epideacetylfusidic acid; 13,
fusidic acid; 14, 16-epideacetylfusidic acid-
21,16-lactone; 15, deacetylfusidic acid-
21,16-lactone; 16, 11-deoxyfusidic acid.
U, unknown impurity.
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the DOW chemical company, Methocel (HPMC) also possesses
emulsifying properties and can act as a surfactant in solution. It
was therefore considered theoretically possible that HPMC may
help to increase the solubility of BV in the aqueous phase leading
to an increased rate of isomerization. After investigation the
increased rate of isomerization was found to be due to this variant
having a pH value of 6.0 (in contrast to the other variants which
had pH values of 5.0 ± 0.2).
It was known from the studies of Bundgaard and Hansen17 that
the kinetics of the transesterification of BV to the 21-valerate
ester in aqueous solution is pH dependent. It was therefore
considered likely that the shift in pH of the cream from 5 to 6 was
responsible for the increase of the isomerization rate. When the
pH of the cream was kept constant, the concentration of HPMC
had no influence on the isomerization rate. Experiments in
aqueous media later showed that the pH increases with increasing
HPMC concentration.
Literature studies indicate that the presence of trace metals
in pharmaceutical preparations can cause degradation of
glucocorticoids18,19. For this reason, the influence of the
presence of the chelating agent disodium edetate on the degrad-
ation rate of BV was investigated. The results did not indicate an
improvement as compared to variant B. It was concluded that
metal ions are not a determining factor with regard to the
isomerization rate of BV.
The suspension of the API in the aqueous phase did not
influence the isomerization rate, indicating that the presence of
water alone is not sufficient to initiate the isomerization process.
This was perhaps to be expected since BV is practically insoluble
in water20. This observation, however, suggested that the API
must be in solution for the isomerization to take place and,
furthermore, that some component of the cream must be
enhancing the solubility of BV in the aqueous phase. Since it
had been observed that a reduction of the concentration of S-20
may lead to an increased stability, it was suspected that the
emulsifier was aiding the dissolution of the suspended BV crystals
into the aqueous phase of the cream.
Replacing S-20 with S-21 appeared to decrease the isomeriza-
tion rate in the above experiment. S-20 and S-21 differ in the
number of oxyethylene (–OC2H5) groups attached to the stearic
acid chain. Both substances have very similar HLB (hydrohilic–
lipophilic–balance) values (15.3 and 15.7, respectively, according
to the manufacturer) indicating that they are likely to show very
similar solubilities in aqueous solution. It would therefore be
expected that both substances should influence the stability of the
cream formulation to a similar extent. Repeat experiments could
not confirm the initial results and it was finally concluded that
there is no major difference between these substances with regard
to their influence on the isomerization process. However, due to
commercial and regulatory considerations it was decided to
employ S-21 in all further experiments.
Optimization – round II
The results of the initial- and optimization experiments demon-
strated that reducing the content of S-20 from 5.00% (variants A,
B and C) to 3.65% (variant D) and further to 2.14% (variant E)
significantly slowed the rate of isomerization. Consequently,
further trial batches were produced containing less S-21 and with
varying quantities of CSO. The goal was to find the optimum
concentration of these components which would provide the
lowest rate of isomerization without compromising the physical
stability of the cream. The proportions of liquid paraffin and
vaseline in the cream were also adjusted with the aim of
improving the physical stability of the preparation. The
accelerated stability studies demonstrated that maximum phys-
ical- and chemical stability was achieved with 1.5% S-21 and
5.5% CSO (Variant F). Further reducing the S-21 concentration to
1.00% did not appear to bring further improvement. Under real
time conditions variant F showed no apparent increase of
betamethasone-21-valerate content after 1 month and 53%
increase over a period of 30 months storage.
Optimization of the concentrations of S-21 and CSO resulted
in an increased chemical stability of BV, while optimization of the
proportions of vaseline and liquid paraffin lead to an increased
physical stability of the cream preparation. In order to demon-
strate definitively that the reduction of the concentrations of the
emulsifier had lead to the increased stability of BV, and not other
parameters, for example the adjustment of the vaseline and
paraffin quantities, the concentration of S-21 in variant F was
increased to the initial concentration present in variants A, B and
C, i.e. 5.00%. The relative proportions of vaseline, paraffin and
CSO, as well as all other excipients remained equivalent to the
optimized variant F. The results demonstrated clearly that an
increase of the concentration of the primary emulsifier, S-21,
leads to an increase of the isomerization rate.
Effect of pH on the isomerization rate of BV
The effect of pH on the isomerization rate of BV was investigated
in both aqueous solution using appropriate buffers and in the
cream preparation itself. As shown in Figure 3(c) the API appears
stable in aqueous solution at pH values between 2.2 and 4.2 with
an optimum at &pH 3.2. This is in good agreement with the
reported literature21. At pH values above 4.2 the rate of
isomerization increases gradually, then increasing very rapidly
Table 2. The percentages of S-20, CSO and HPMC in the optimized versions of variants B and E.
Variant E Variant E (with warming) Variant B (0.5% HPMC) Var. B (1.0% HPMC)
Article Description Proportion in mass % Proportion in mass % Proportion in mass % Proportion in mass %
1 Macrogolstearylether-20 (S-20) 2.1 2.1 5.0 5.0
2 Cetylstearyl alcohol (CSO) 7.9 7.9 5.0 5.0
3 Hypromellose (HPMC) 0.5 0.5 0.5 1.0
Variant B (0.1% Na2EDTA) Variant B (with S-21) Variant B (API in H2O)
Article Description Proportion in mass % Proportion in mass % Proportion in mass %
1 Macrogolstearylether-20 ‘‘or’’
–21 (S-20/ S-21)
5.0 5.0 5.0
2 Cetylstearyl alcohol (CSO) 5.0 5.0 5.0
3 Hypromellose (HPMC) 1.0 1.0 2.0
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above pH 6.2. Complete isomerization of BV was observed after
48 h at pH 8.2.
The situation is similar in the cream preparation. At pH values
between 2.7 and 5.3 the drug substance was relatively stable,
although some degradation still occurred. At higher pH values,
e.g.46, the isomerization rate increases very rapidly giving rise to
complete isomerization within 1 month at pH 8 and 40 C/75%
RH. A pH range of between 4.5 and 5.5 was chosen for the cream
since this range is a compromise between skin tolerability and
drug stability. Lower pH values are generally considered too
acidic for topical treatment and higher pH values would
compromise the stability of the API.
Experiments in aqueous solution
During manufacture of the cream preparation, BV is suspended in
liquid paraffin before being added to the rest of the ingredients
during the last stage of manufacture. In order to confirm that the
isomerization only occurs when an aqueous medium is present,
the stability of BV in liquid paraffin was investigated (see
Experimental Procedures, Section ‘‘Solubility in paraffin’’). The
conditions employed were known to give rise to isomerization in
aqueous solution. No isomerization was observed in liquid
paraffin, indicating that water is necessary for the isomerization
to take place. Since the API crystals are initially suspended in the
cream, the BV must dissolve into the aqueous (continuous) phase
of the O/W emulsion in order for the isomerization to occur.
This hypothesis was further investigated by experimentation in
aqueous solution.
Effect of S-21 concentration on the solubility of BV in aqueous
medium
In order to examine the influence of the concentration of S-21 on
the solubility and isomerization rate of BV in aqueous solution,
solubility measurements were carried out (see Experimental
Procedures, Section ‘‘Solubility in aqueous solutions of emulsi-
fier’’). It was found that all solutions had a pH of 5.3 ± 0.2.
Figure 3(d) shows how the solubility of BV increases in aqueous
solution with increasing concentration of S-21. In contrast, the
rate of isomerization does not increase proportionally because of
the relatively favorable pH of 5.3 which prevents a rapid
isomerization (see Section ‘‘Solubility in aqueous solutions of
emulsifier’’). It was concluded that S-21 increases the solubility
of BV in aqueous media. In the drug product formulation the BV
crystals are also exposed to both the water phase and to the
emulsifier and it was suspected that in this case the increased
emulsifier concentration also leads to an increased solubility
of BV.
Effect of variation of both S-21 concentration and pH
The effect of simultaneously varying both S-21 concentration and
pH was investigated by preparing samples in the same fashion as
described in Section ‘‘Effect of S-21 concentration on the
solubility of BV in aqueous medium’’, the only difference being
that appropriate buffers were employed over the pH range 3.2–7.2
(Figure 4). At higher pH values, e.g. 7, and low concentrations of
S-21, the rate of isomerization remains low, indicating that the BV
must be solubilized into solution before the isomerization can take
place. However, at lower pH values, e.g. pH 3, and higher
concentrations of S-21, the rate of isomerization remains low,
indicating that the isomerization only takes place when the pH
conditions allow. The results indicate that the BV must first be
solubilized into the aqueous phase where the rate of isomerization
is then pH dependent. In the cream formulation, this means that
higher concentrations of emulsifier more rapidly solubilize the
BV thus increasing the overall concentration of drug substance
present in the aqueous phase.
Microscopy
The effect of changing the concentration of emulsifier on the
isomerization rate was also examined by microscopy. This
technique allows for the direct observation of the suspended BV
crystals in real time. However, the BV employed in the cream
formulation was micronized (particle size distribution of
90%55mm) which made the observation of the crystals difficult
in such a complex sample matrix. This problem was overcome by
employing non-micronized BV with a much larger particle size
(90%5110mm), thus making the observation of any potential
dissolution phenomena much easier. One batch of each of Variant
B and Variant F was prepared with non-micronized BV and placed
on stability for 1 year under accelerated conditions (40 C/75%
RH). The microscopic profiles and chemical stability of the
creams were analyzed after 1, 2, 3, 6, 9 and 12 months.
The micrographs presented in Figure 5 demonstrate that the
BV crystals in Variant B (with 5% S-21) disintegrate and dissolve
over time. After 12 months storage at 40 C/75% RH there are no
visible crystals remaining in the cream. The data from the
chemical analysis also indicate that the BV is rapidly degrading
under these conditions. In contrast, the BV crystals in Variant F
remain largely unchanged, a well-defined crystal structure being
present throughout the entire study. The isomerization rate of BV
is also much slower in variant F than in variant B, as confirmed by
the chemical data. This study further supports the hypothesis that
increasing the concentration of emulsifier leads to a more rapid
dissolution of the suspended crystals.
Discussion and conclusions
The current study has demonstrated that the pH of a topical
vehicle is not the only factor to be considered when formulating
BV. The stability of BV in a given preparation may be influenced
by adjusting the concentration of the emulsifier to such a degree
that either practically no isomerization occurs over the shelf-life,
or alternatively, that complete isomerization occurs within a short
period of time. An increased concentration of macrogolstear-
ylether has been shown to enhance the solubility and isomeriza-
tion rate of BV in the aqueous phase of a hydrophilic cream.
Maximum chemical stability was achieved at a concentration
51.5% (w/w) of this substance in the preparation. The data
suggest that the co-emulsifier CSO does not play a significant role
in the solubilization/isomerization process.
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Figure 4. Effect of pH and emulsifier concentration on the isomerization
rate of BV (pH 3.2–7.2).
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Overall, the factors influencing the rate of isomerization in a
hydrophilic cream in which BV is suspended can be summarized
as follows (Figure 6):
 Water is necessary for the isomerization to take place.
Transesterification will not occur in a non-aqueous environ-
ment, e.g. fatty ointment.
 At high concentrations of emulsifier (e.g. 5%) and higher pH
values (e.g.46) there is a rapid rate of isomerization.
 At high concentrations of emulsifier (e.g. 5%) and lower pH
values (e.g. 54) there is a moderate rate of isomerization,
which is pH dependent.
 At low concentrations of emulsifier (e.g. 1%) and higher pH
values (e.g. 46) there is a moderate rate of isomerization,
which appears to be mainly dependent on the solubility of the
API in the aqueous phase.
 At low concentrations of emulsifier (e.g. 1%) and lower pH
values (e.g.54) there is a slow rate of isomerization since the
concentration of BV in the aqueous phase is very low and the
quantity which is dissolved isomerizes at a slow rate due to the
low pH.
In order to optimize the stability of BV in a hydrophilic
cream suspension, both the concentration of emulsifier and the pH
value should be kept as low as possible. It seems reasonable to
hypothesize that the instabilities observed on dilution of BV
creams with emulsifying ointment and other emulsifier containing
diluents in previous studies11,12 may have been due to an
increased solubility of BV in the aqueous phase. This study
demonstrates that the choice and concentration of emulsifier
chosen for a topical vehicle containing BV is likely to be of
critical importance when developing a formulation. Equally, the
Figure 5. Micrographs of BV crystals in variants B and F after storage at 40 C/75% RH.
Figure 6. Schematic of the effect of pH and
emulsifier concentration on the isomerization
rate of BV in a hydrophilic cream.
DOI: 10.3109/10837450.2016.1143003 Formulation factors affecting the isomerization of betamethasone valerate 543
diluent used for diluting proprietary marketed corticosteroid
preparations must be chosen with care, taking not only pH, but
also emulsifier concentration into account. Based on the observed
mechanism, it seems plausible that the findings are also relevant
for other topical glucocorticoids esterified at the C17 position,
although this remains to be confirmed.
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